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insulin results in renoprotection by reducing oxidative stress
in an earlier period, whereas PGZ does so by inhibiting
transforming growth factor-b production in a later period.3
The above-mentioned points need to be clarified before the
renoprotective effect of thiazolidinedione can be applied to
clinical practice in a large scale.
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Liu et al. are apparently concerned mainly with the
potential benefits of a combination of pioglitazone (PGZ)
and insulin treatment in type II diabetes mellitus. In
contrast, as stated in the introduction of our paper,1 we
evaluated whether, despite similar or even worse glucose
levels, renoprotection achieved by PGZ monotherapy (and
its attendant correction of hyperinsulinemia) differed from
that obtained with insulin alone. We did not include,
therefore, a group treated with both insulin and PGZ. In
parenthesis, in a recent review article, Sarafidis and Bakris2
summarized all human clinical and experimental animal
studies relevant to the renoprotective benefits of thiazoli-
dinediones: only 1 out of 29 studies allowed the use of
insulin in combination with thiazolidinediones.
For similar reasons, creatinine clearance was evaluated
only at the end of the study, as we were not interested in a
PGZ–insulin combined treatment.
We agree with Liu et al. that higher PGZ doses might
have further improved glucose control, but a search for a
maximal effect on glucose was beyond the rationale of our
study.
Liu et al. speculate on the transient effect of insulin on
proteinuria. We are unable to comment their hypothesis as
our study was not designed to assess this issue. We should
point out, however, that, contrary to the statement by Liu
et al., Schena and Gesualdo3 do not consider the effect of
insulin treatment on renal oxidative stress.
Our findings demonstrate only that, in a type II diabetic
rat model, PGZ monotherapy improves renoprotection
above that obtained by insulin alone. We speculate that
this benefit is due to fall in circulating insulin levels,
probably through a reduction of transforming growth
factor-b expression. We wholeheartedly agree with Liu
et al. that extension of our conclusions to human disease
requires further clinical studies. In this context, they will
be interested to learn that, in Japan only, a large clinical
study is already in progress based on the potential clinical
benefit of thiazolidinediones in type II diabetics, that is,
the Japan Diabetes Outcome Intervention Trial (3000
patients are to be enrolled),4 and another clinical study is
in the planning stage based on the clinical benefit of PGZ
in type II diabetics, that is, Pioglitazone Multicenter
Intervention Clinical Trial in Hospital of Tohoku Region
Improving Nephropathy, Oxidative Stress, Kidney Injury,
Urinary Albumin Excretions study (200 patients; S Ito,
personal communication).
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To the Editor: The article ‘Early steroid treatment improves
the recovery of renal function in patients with drug-induced
acute interstitial nephritis’ has great significance in clinical
practice but needs to be interpreted with caution.1
In this multicenter retrospective analysis the role of
steroids in patients with biopsy-proven drug-induced acute
interstitial nephritis was evaluated in 61 patients. The authors
found that final serum creatinine values in patients who were
treated with steroids, especially early in the course of disease
were significantly lower than the untreated group. In this
study patients were categorized as mild, moderate, and severe
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